TRAVERE THERAPEUTICS

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

17 مارس 2025 07:01:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 مارس 2025 17:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Participate at Upcoming Investor Conferences

24 فبراير 2025 16:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

20 فبراير 2025 16:01:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

13 فبراير 2025 16:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS

11 فبراير 2025 07:01:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Provides Corporate Update and 2025 Outlook

13 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 يناير 2025 16:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

25 نوفمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 نوفمبر 2024 17:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

12 نوفمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

07 نوفمبر 2024 21:05:37 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Announces Proposed Public Offering of Common Stock

07 نوفمبر 2024 16:01:18 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

04 نوفمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Reports Third Quarter 2024 Financial Results

31 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

26 أكتوبر 2024 07:01:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Report Third Quarter 2024 Financial Results

21 أكتوبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

17 أكتوبر 2024 07:01:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

14 أكتوبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

26 سبتمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire